Converge Bio Secures $25 Million to Advance AI-Powered Drug Discovery
Converge Bio, a startup specializing in artificial intelligence for drug discovery, has raised $25 million in a Series A funding round led by Bessemer Venture Partners, with notable support from executives at Meta, OpenAI, and Wiz.
